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Abstract Human epidermal growth factor receptor 2
(HER2) is involved in the pathogenesis and poor outcomes
of several types of cancer, including advanced gastric and
gastroesophageal junction cancer. Molecular-targeted
drugs, such as trastuzumab, which prolong overall survival
and progression-free survival in HER2-positive breast
cancer, may also be beneficial in patients with HER2-
positive gastric cancer. Several studies have examined this
possibility, such as the Trastuzumab for Gastric Cancer
trial. In this context, the first part of this review provides an
update on our knowledge of HER2 in breast and gastric
cancer, including the detection and prognostic relevance of
HER2 in gastric cancer. The second part of the review
discusses the results of pivotal clinical trials that examined the
potential for using trastuzumab to treat this disease. This sec-
tion also summarizes the trials that have been conducted or that
are underway to determine the optimal uses of trastuzumab in
gastric cancer, including its use as monotherapy and continu-
ation beyond disease progression. The final section discusses
the future prospects of other anti-HER2 drugs, including la-
patinib, trastuzumab emtansine, and pertuzumab, for the
treatment of HER2-positive gastric cancer. The introduction of
trastuzumab led to the establishment of a new disease entity,
‘‘HER2-positive gastric cancer,’’ similar to HER2-positive
breast cancer. It is expected that more anti-HER2 drugs will be
developed and introduced into clinical practice to treat
HER2-positive cancers, including gastric cancer.
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Introduction
Up to 30 % of breast cancers overexpress human epidermal
growth factor receptor 2 (HER2, c-erbB2), and HER2
positivity is associated with significantly worse outcomes
than HER2-negative breast cancer [1]. Trastuzumab, a
monoclonal antibody directed against HER2, was one of
the first molecular-targeted drugs to be developed and was
originally introduced for the treatment of HER2-positive
metastatic breast cancer. Its approval in this setting was
based on two pivotal studies, which showed the efficacy of
trastuzumab administered with paclitaxel [2] or trast-
uzumab alone as first-line therapy [3]. Studies have since
demonstrated its efficacy for treating early breast cancer
when used with either adjuvant [4–6] or neoadjuvant
[7–9] chemotherapy, conferring prolonged survival and
improved outcomes compared with the established thera-
pies using cytotoxic agents alone. Over the last decade,
trastuzumab has revolutionized the treatment of HER2-
positive breast cancer and improved its outcomes [10].
Based on these findings, trastuzumab is now considered a
key drug for treating HER2-positive breast cancer, which
has been established as a major disease subtype of breast
cancer.
With increasing understanding of the molecular biology
of HER2, and the availability of genomics and proteomics
analyses, it has now been recognized that HER2 is impli-
cated in other severe forms of cancer, notably gastric
cancer. Therefore, the aims of this review are to provide an
update on our knowledge of HER2 in the context of gastric
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cancer and to describe the clinical trials that have examined
the potential of using trastuzumab to treat this disease, such
as the Trastuzumab for Gastric Cancer (ToGA) trial [11],
or are currently underway.
Gastric cancer and the biological relevance of HER2
HER2 is a proto-oncogene encoded by ERBB2 on chro-
mosome 17. It is a member of the HER family and con-
sists of four plasma membrane-bound receptor tyrosine
kinases that transmit extracellular signals to initiate cel-
lular signaling pathways via mitogen-activated protein
kinase, phosphoinositide 3-kinase, phospholipase C, pro-
tein kinase C, and signal transducer and activator of
transcription. Following early studies [12–14], it has now
become clear that HER2 is expressed in many tissues,
including the breast, gastrointestinal tract, kidney, and
heart. Its major role in these tissues is to promote cell
proliferation and suppress apoptosis, which may facilitate
excessive/uncontrolled cell growth and tumorigenesis
[15–17].
Overexpression/amplification of HER2/ERBB2 in breast
cancer, resulting in HER2-positive subtypes, is associated
with very poor prognosis compared with HER2-negative
breast cancer [1, 18]. HER2-positive breast cancer is also
associated with increased risk of local growth and distant
metastasis. Many studies, including several conducted in
Japan, have demonstrated that HER2 is also present in
other cancers, particularly in gastric cancer [19–22]. Con-
sequently, many studies have evaluated the relationship
between HER2 status and prognosis in patients with gastric
cancer [23–33]. Unlike in breast cancer, the studies in
gastric cancer to date have yielded inconsistent findings
regarding the prognostic relevance of HER2. Some showed
that HER2 positivity was associated with a significantly
worse prognosis [23, 26, 28, 31, 32], whereas others found
no association between HER2 status and prognosis [25,
33], or that median overall survival was longer in HER2-
positive than in HER2-negative patients [24, 25]. There-
fore, the relationship between HER2 status and prognosis
of gastric cancer patients remains controversial.
In the context of breast cancer, the American Society of
Clinical Oncology/College of American Pathologists noted
Table 1 Prevalence of HER2 positivity in patients with gastric cancer
Study Country n Determination of HER2 status HER2-positive (%) Prognosis
Takehana et al. [76] Japan 352 IHC 2?/IHC 3? 8.2 n/a
Tanner et al. [32] Finland 231 CISH? 36.6 ??
Park et al. [31] Korea 182 IHC 2?/IHC 3? 15.9 ??
CISH ?/FISH? 3.8
Yano et al. [77] Japan 200a IHC 2 ?/IHC 3? 23.0 n/a
199a FISH 27.1
Kim et al. [78] Korea 248 EMA labelb 6.0 –
Matsubara et al. [79] Japan 87 [10 % 18.0 –
Barros-Silva et al. [80] Portugal 463 IHC 2?/IHC 3? 9.3 ?
EMA labelb 8.0
Yan et al. [81] Singapore 128 FISH? 11.7 ?
IHC 3? 9.4
Yan et al. [82] China 145 EMA labelb 10.3 ?
Lee et al. [83] Australia 178 EMA labelb 20.2 n/a
Liu et al. [84] China 775 EMA labelb 12.1 ?
Giuffre` et al. [85] Italy 109 EMA labelb 21.1 ??
Tsapralis et al. [86] Greece 120 IHC 2?/IHC 3? 16.6 –
ISH? 15.8
Terashima et al. [33] Japan 829 IHC 3? or IHC 2 ?/DISH? 9.0 –
Wang et al. [87] China 102 EMA labelb 14.7 –
Kim et al. [28] Korea 111 FISH? 9.0 ??
Halon et al. [88] Poland 78 IHC 2?/IHC 3? 29.5 –
n/a not applicable, — no association was found between HER2 expression and prognosis, ? HER2 expression was partially associated with poor
prognosis, ?? HER2 expression was associated with poor prognosis, EMA European Medicines Agency
a Invasive intestinal cancer only
b IHC 3? or IHC 2?/FISH-positive
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that as many as 20 % of HER2 tests performed may be
inaccurate [34], which may also influence studies
attempting to determine the frequency of HER2-positive
gastric cancer. Because of differences in the examination
method and objective criteria, the frequency of HER2-
positive gastric cancer varies considerably between studies,
ranging from 6.0 to 29.5 % in earlier studies (Table 1). In
an effort to address these inconsistencies, the investigators
in the ToGA trial conducted a validation study to assess the
immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH) protocols for testing HER2 status in
advanced gastric cancer [35]. Tissue specimens from 3,807
patients in 24 countries were collected and analyzed at a
central laboratory using both IHC and FISH methods [11,
36]. HER2 status was defined as positive (IHC 3? or
FISH-positive) based on the surgical or biopsy specimen
staining patterns (Table 2). Notably, there were no marked
racial differences in HER2 expression; instead, differences
in HER2 expression were mainly attributed to the site of
the primary tumor (gastric vs. gastroesophageal junction)
and histological type [36]. The criteria for HER2 status
also differ between breast cancer and gastric cancer
because of differences in the IHC staining pattern for
HER2 between these sites [35].
HER2 status is mainly assessed by IHC or FISH using
biopsy or surgical specimens. Based on the results of the
ToGA study, trastuzumab was approved for HER2-positive
gastric cancer, which is defined as IHC 3? or FISH-posi-
tive in the USA and Japan. Conversely, HER2-positive
gastric cancer is defined as IHC 3? or as IHC 2 ? plus
FISH-positive in Europe [37]. The guidelines for HER2
testing of gastric cancer developed by the Japanese Society
of Pathology [38] recommend that HER2 testing should be
routinely performed in patients with metastatic or recurrent
gastric cancer. The testing algorithms developed for HER2
involve IHC first, followed by FISH for IHC 2? patients.
In order to confirm the frequency of HER2-positive gastric
cancer found in ToGA, a prospective study is now under-
way to determine the prevalence of HER2-positive cancer
in Japanese patients [39].
The results of the studies described above have provided
a clear rationale for the use of drugs targeting HER2, such
as trastuzumab, to treat gastric cancer. Accordingly, the
aims of the next part of this review are to summarize the
results of studies in this setting and identify opportunities
for further research.
Efficacy and safety of trastuzumab in gastric cancer:
the ToGA trial
The ToGA trial was a prospective, phase 3, open-label trial
in which patients with HER2-positive advanced gastric or
gastroesophageal junction cancer were randomly allocated
to receive either trastuzumab in combination with chemo-
therapy or chemotherapy alone [11]. Chemotherapy was
given every 3 weeks for six cycles. Trastuzumab was
administered at a dose of 8 mg/kg on day 1 of the first
cycle and then at 6 mg/kg every 3 weeks until disease
progression, unacceptable toxicity, or withdrawal of con-
sent. Overall, 3,803 patients were screened for the study,
810 were HER2-positive (based on the criteria listed in
Table 2), 594 were randomized, and 584 received study
treatment and were analyzed. The general characteristics of
patients in the trastuzumab plus chemotherapy (n = 294)
and chemotherapy-alone (n = 290) groups were similar,
including age (59.4 vs. 58.5 years), sex (proportion of men:
77 vs. 75 %), chemotherapy regimen (capecitabine and
cisplatin: 87 vs. 88 %; fluorouracil and cisplatin: 13 vs.
12 %), and primary tumor site (stomach: 90 vs. 83 %;
gastroesophageal junction: 20 vs. 17 %). Overall, 97 % of
patients in both groups had metastatic disease at study
entry, and just under half were classified as FISH-positive/
IHC 3 ? (45 vs. 43 %).
The primary endpoint of the study was overall survival,
which was defined as the time from randomization to death
from any cause. As shown in Fig. 1a, overall survival was
significantly longer in patients receiving trastuzumab plus
chemotherapy compared with chemotherapy alone, with an
increase of 2.7 months in median overall survival [13.8 vs.
11.1 months; hazard ratio (HR): 0.74; 95 % confidence
interval (CI): 0.60–0.91; P = 0.0046]. Progression-free
survival was also extended by trastuzumab plus chemo-
therapy compared with chemotherapy alone (6.7 vs.
5.5 months; HR: 0.71; 95 % CI: 0.59–0.85; P = 0.0002)
(Fig. 1b). The overall response rate in the trastuzumab plus
chemotherapy group was 47 % (complete response: 5 %;
partial response: 42 %) and was significantly greater than
that in the chemotherapy-alone group (35 %; P = 0.0017;
complete response: 2 %; P = 0.0599; partial response:
32 %; P = 0.0145). The duration of response (6.9 vs.
4.8 months; P \ 0.0001) was also significantly longer in
the trastuzumab plus chemotherapy group.
Pre-planned and post hoc exploratory analyses of sub-
groups of patients also revealed that overall survival was
longer in patients with higher HER2 expression, as deter-
mined by IHC and FISH (i.e., IHC 3? or IHC 2?/FISH-
positive), than in patients with lower HER2 expression (i.e.,
IHC 0 or 1?/FISH-positive). Among patients with higher
HER2 expression, survival was significantly extended by
trastuzumab in combination with chemotherapy compared
with chemotherapy alone (16.0 vs. 11.8 months; HR: 0.65;
95 % CI: 0.51–0.83) (Fig. 2). Based on the results of these
tests, trastuzumab therapy is strongly recommended for
patients with IHC 3? or IHC 2?/FISH-positive (high
HER2 expression) in clinical practice in Japan.
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The incidence of adverse events was similar in both
groups, with grade 3 or 4 events occurring in 68 % of
patients in both groups, the most common of which were
neutropenia, anemia, nausea, and vomiting.
The results of this study showed that trastuzumab in
combination with chemotherapy significantly improved
overall survival in patients with HER2-positive advanced
gastric or gastroesophageal cancer compared with chemo-
therapy alone, and this improvement was particularly sig-
nificant in patients with high HER2 expression. It is also
notable that trastuzumab did not increase the incidence of
adverse events associated with chemotherapy and that the
rate of cardiac events (e.g., cardiac failure and decreases in
left ventricular ejection fraction) was low.
Trastuzumab as maintenance therapy
In terms of the optimal treatment of patients with HER2-
positive cancer, several regimens using trastuzumab have
been proposed and tested in clinical settings. Trastuzumab
monotherapy is used as maintenance therapy for patients
with breast cancer based on the study by Vogel et al. [3],
who reported an objective response rate of 26 %, which
was driven by the response rate in patients with HER2
expression scored as IHC 3? (35 %); no patient with IHC
2? expression showed a response. In that study, trast-
uzumab was administered with a 4 mg/kg loading dose
followed by 2 mg/kg dose weekly or a 8 mg/kg loading
dose followed by 4 mg/kg weekly. In the Herceptin
Adjuvant (HERA) trial, women with HER2-positive
advanced breast cancer were randomly assigned to 1 or
2 years of treatment with trastuzumab or observation after
locoregional therapy and at least four cycles of neoadjuvant
or adjuvant chemotherapy [4]. The primary article pre-
sented the results for the 1-year and observation groups,
where Kaplan–Meier analysis showed that 1 year of trast-
uzumab maintenance therapy was associated with signifi-
cantly greater disease-free survival (85.8 vs. 77.4 %;
P \ 0.0001) and distant recurrence-free survival (90.6 vs.
82.8 %; P \ 0.0001), although not overall survival (96.0
vs. 95.1 %; P = 0.26), compared with observation alone,
with a median follow-up of 1 year [4]. However, at a
median follow-up of 2 years, the risk of death was signif-
icantly lower in patients treated with trastuzumab for
1 year compared with observation alone (HR: 0.66; 95 %
CI: 0.47–0.91; P = 0.0115), as was the risk of a disease-
free survival event (HR: 0.64; 95 % CI: 0.54–0.76;
P \ 0.001) [40]. At a median follow-up of 4 years, there
remained a significant disease-free survival benefit of
1 year of trastuzumab therapy compared with observation
alone (HR: 0.76; 95 % CI: 0.66–0.87; P \ 0.0001),
although the risk of death was no longer significantly dif-
ferent (HR: 0.85; 95 % CI: 0.70–1.04; P = 0.11) [41].
Disease-free survival and overall survival were also sig-
nificantly greater at a median follow-up of 8 years in
patients given 1 year of trastuzumab maintenance therapy
compared with observation alone (HR: 0.76, P \ 0.0001;
and HR: = 0.76, P = 0.0005, respectively), demonstrating
the durable effects of trastuzumab on survival and pre-
venting disease recurrence [42].
Initial data for patients allocated to 2 years of trast-
uzumab maintenance therapy were published in 2012 [42],
with a median follow-up of 8 years. In that analysis, the
unadjusted HR for any disease-free survival event in the
2- vs. 1-year trastuzumab groups was 0.99 (95 % CI:
0.85–1.14; P = 0.86). Overall survival was also compa-
rable in both groups (HR: 1.05; 95 % CI: 0.86–1.28;
P = 0.63). Based on these data from the HERA trial, the
authors concluded that 1 year of trastuzumab maintenance
therapy should be considered as the standard of care for
patients with HER2-positive advanced breast cancer.
Table 2 Immunohistochemistry scoring for HER2 expression in gastric and gastroesophageal junction cancer used in the ToGA trial [11]
Score Surgical specimen staining pattern Biopsy specimen staining pattern HER2
overexpression
assessment
0 No reactivity or membranous reactivity in \10 % of
tumor cells
No reactivity or no membranous reactivity in any tumor cell Negative
1? Faint or barely perceptible membranous reactivity
in C10 % of tumor cells; cells are reactive only in
part of their membrane
Tumor cell cluster with a faint or barely perceptible
membranous reactivity irrespective of percentage of tumor
cells stained
Negative
2? Weak to moderate complete, basolateral or lateral
membranous reactivity in C10 % of tumor cells
Tumor cell cluster with a weak to moderate complete,
basolateral or lateral membranous reactivity irrespective of
percentage of tumor cells stained
Equivocal
3? Strong complete, basolateral or lateral membranous
reactivity in C10 % of tumor cells
Tumor cell cluster with a strong complete, basolateral or
lateral membranous reactivity irrespective of percentage of
tumor cells stained
Positive
Reprinted with permission from Elsevier Ltd
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To expand these breast cancer findings of trastuzumab
monotherapy into the setting of gastric cancer, a pilot study
was conducted in which patients who progressed while on
chemotherapy for metastatic or locally advanced HER2-
positive gastric cancer were treated with trastuzumab
monotherapy [43]. However, the study only involved four
patients; therefore, additional studies are needed to confirm
the potential of trastuzumab monotherapy.
In the early part of the ToGA trial, patients in the
trastuzumab group received six cycles of chemotherapy in
combination with trastuzumab and then continued
trastuzumab monotherapy until disease progression.
Patients in the trastuzumab group could also continue
trastuzumab monotherapy until disease progression, even if
unacceptable toxicity of chemotherapy occurred during the
planned six cycles. By contrast, patients in the control
group entered an observation period after completion of six
cycles of chemotherapy or after withdrawal of chemo-
therapy during the planned six cycles. Since August 2007,
extended cycles of chemotherapy were allowed after con-
sidering the risk/benefit ratio for each patient. Thus, the
ToGA protocol allowed for trastuzumab to be continued
Fig. 1 Median survival (a) and
progression-free survival (b) in
the ToGA trial [11]. HR hazard
ratio, CI confidence interval.
Reprinted with permission from
Elsevier Ltd
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while chemotherapy was discontinued or the doses
reduced, even if notable toxicities occurred that were
possibly caused by chemotherapy. In order to estimate the
efficacy of trastuzumab as maintenance therapy in the
ToGA trial, the duration of trastuzumab monotherapy in
the trastuzumab arm was compared with the observation
period of the chemotherapy-alone arm. As shown in Fig. 3,
159 patients (54.1 %) received trastuzumab monotherapy
after combination therapy with trastuzumab (n = 294)
[44]. Only 97/290 patients (33.4 %) in the chemotherapy-
alone group experienced chemotherapy-free periods. Rea-
sons for switching to trastuzumab monotherapy included
completion of six cycles of chemotherapy (125/159, 79 %),
physician’s judgment (22/159, 14 %), or an adverse event
associated with chemotherapy (12/159, 8 %). Although
statistical comparison between the trastuzumab mono-
therapy periods and the chemotherapy-free periods was not
performed, the former was apparently longer than the lat-
ter. Continuation of trastuzumab after discontinuation of
chemotherapy likely contributed to the prolonged survival
in the trastuzumab plus chemotherapy group. The ToGA
trial therefore indicated that starting trastuzumab in com-
bination with chemotherapy and then continuing trast-
uzumab monotherapy until disease progression extended
overall survival in patients with gastric cancer.
The survival advantage of second-line chemotherapy
was recently confirmed in a German study comparing iri-
notecan vs. best supportive care for gastric cancer [45] and
in a South Korean study comparing salvage chemotherapy
(docetaxel or irinotecan) plus best supportive care vs. best
Fig. 2 Results of the ToGA
trial [11]. a Pre-planned
exploratory and post hoc
exploratory analyses of patients
stratified by HER2 status.
*n = 561; patients with no
immunohistochemistry (IHC)
data (n = 7) or IHC 3? tumors
with no fluorescence in situ
hybridization (FISH) data
(n = 16) were excluded from
the analysis. n = 577; patients
with no IHC data were excluded
from the analysis. b Overall
survival in patients with higher
HER2 expression (IHC 2? and
FISH-positive tumors or IHC






supportive care alone [46]. As the adverse reactions of
trastuzumab alone were less toxic than those of the
cytotoxic chemotherapies in the ToGA trial, the patient’s
physical condition could be improved by minimizing
Fig. 3 Number of cycles of combination drugs administered in individual patients enrolled in the ToGA trial [11] in the control (a) or
trastuzumab (b) groups
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adverse reactions caused by cytotoxic agents while using
trastuzumab monotherapy to control disease progression.
This improvement might also be attributed to the ease of
performing second-line chemotherapy or further treatment,
especially if there is a chemotherapy-free period before
introducing second-line chemotherapy.
A case report highlighted the long-term survival
(3 years and 6 months) of a Japanese patient included in
the ToGA trial who had HER2-positive, unresectable
advanced gastric cancer. This patient received trastuzumab
plus capecitabine and cisplatin as initial therapy and con-
tinued maintenance therapy with trastuzumab alone for 47
cycles after completing 6 cycles of chemotherapy [47].
The German HerMES non-interventional observational
study evaluated the efficacy, safety, and feasibility of
trastuzumab in untreated patients with HER2-positive
metastatic gastric cancer. In an interim analysis of 165
patients treated with regimens containing trastuzumab
between April 2010 and April 2012, 20 % of patients
continued trastuzumab alone after six cycles of chemo-
therapy, while [40 % of these patients received trast-
uzumab alone after ten cycles of chemotherapy, prompting
the author to speculate that maintenance therapy with
trastuzumab after chemotherapy is a preferred treatment
option [48]. The median progression-free survival in that
study was 6.9 months, and the overall rate of adverse
events was 30.3 %. Grade 3–5 adverse events were rare,
and the most common included vomiting (1.82 %) and
general physical health deterioration (1.82 %).
Several other studies in breast cancer have also shown
favorable responses to trastuzumab monotherapy [49, 50],
which suggests that similar outcomes may be evident in
gastric cancer.
Regarding the rationale for continuation of trastuzumab
monotherapy, the ToGA (as shown in Fig. 3) and HERA
trials demonstrated that continuous treatment with a single
agent was capable of inhibiting HER2-positive tumor
growth. However, this interpretation needs support from
prospective comparative studies. To reproduce the effect of
trastuzumab on the overall survival benefit observed in the
ToGA trial, it is recommended that trastuzumab mono-
therapy be continued after completing chemotherapy in
routine clinical practice.
Should trastuzumab be continued beyond progressive
disease?
Another important clinical issue is whether or not to con-
tinue molecular-targeted drugs upon disease progression.
Currently, anticancer drugs, particularly cytotoxic drugs,
are generally discontinued upon disease progression, and
the patients started on subsequent aggressive treatment. Is
there any evidence to support the validity of this approach,
or should the molecular-targeted drug be continued?
Currently, no studies have examined this approach in the
context of gastric cancer. However, several studies have
been conducted that demonstrated the efficacy of contin-
uing molecular-targeted drugs beyond disease progression
in patients with breast cancer and colorectal cancer
[51–56]. For example, it was recently reported that con-
tinuation of bevacizumab plus fluoropyrimidine-based
chemotherapy beyond first progression in patients with
metastatic colorectal cancer prolongs overall survival and
progression-free survival compared with chemotherapy
alone in the second-line setting [51].
Perhaps the best support for this concept comes from a
randomized study performed in Germany in HER2-positive
breast cancer [56]. In this study, patients with disease
progression during trastuzumab-based therapy were ran-
domly assigned to either capecitabine plus trastuzumab or
capecitabine alone. The median time to progression (8.2 vs.
5.6 months; P = 0.0338) and overall survival (25.5 vs.
20.4 months; P = 0.257) were longer, and overall response
(48.1 % vs. 27.0 %; P = 0.0115) was greater in patients
who continued trastuzumab beyond disease progression.
These results provide an answer to the clinical question ‘‘Is
it effective to continue anti-HER2 therapy on disease
progression in patients with metastasis or recurrence of
HER2-positive breast cancer while undergoing trast-
uzumab therapy or after completing the therapy?’’ posed by
the Japanese Breast Cancer Society [57].
The results of these studies suggested that continuing
trastuzumab after progressive disease is a viable option,
although larger, prospective studies are needed to confirm
this approach. Now, several clinical trials in Japan (e.g., [58,
59]) are underway or are being planned to test this approach.
Is there potential for using trastuzumab
as perioperative chemotherapy in gastric cancer?
Perioperative chemotherapy is increasingly being consid-
ered as part of the treatment of various cancers, as it should
allow earlier delivery of systemic treatment to the target
lesion. Numerous studies have already shown favorable
outcomes of perioperative chemotherapy compared with
surgery alone or postoperative chemotherapy in the context
of colorectal liver metastasis [60]. In terms of gastric
cancer, Cunningham et al. [61] reported that a periopera-
tive regimen consisting of epirubicin, cisplatin, and infused
fluorouracil decreased tumor size and stage and improved
progression-free and overall survival compared with sur-
gery alone in patients with gastric cancer. Several case
reports have documented favorable outcomes of trast-
uzumab as part of perioperative chemotherapy for gastric
8 N. Boku
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cancer [62, 63]. Both of these patients had complete
pathological response after trastuzumab-based chemother-
apy. Postmarketing clinical trials are now underway in
Spain and Germany to examine the efficacy of periopera-
tive adjuvant chemotherapy with trastuzumab in patients
with HER2-positive gastric cancer (e.g., [64, 65]). The
results of these studies should support an indication for
trastuzumab as part of a perioperative chemotherapeutic
regimen for treating HER2-positive gastric cancer.
Future prospects: clinical development of new
anti-HER2 drugs
Based on our increasing knowledge of the role for HER2 in
gastric cancer, other agents targeting HER2 are also being
developed for use in this setting, including lapatinib [66,
67]. Lapatinib is an orally active synthetic drug [68, 69]
that is approved in Japan for HER2-positive breast cancer
in combination with capecitabine [70]. Lapatinib inhibits
HER2 signaling by blocking tyrosine kinase activity. In the
Lapatinib (Tykerb) with Paclitaxel (Taxol) in Asian
ErbB2? (HER2?) Gastric Cancer Study (TYTAN), for
example, patients across five Asian countries are to be
randomly assigned to lapatinib (1,500 mg daily) plus
paclitaxel (80 mg/m2 weekly) or paclitaxel alone. The
primary endpoint of the study is overall survival. This
study did not show an improvement in the primary end-
point. However, the efficacy of lapatinib was strongly
suggested in the IHC?3 subset. These results indicate that
the definition of HER2-positive gastric cancer is very
important for the development of new anti-HER2 drugs
[66]. Promising results have also been obtained for other
compounds, including trastuzumab emtansine (T-DM1)
[71] and pertuzumab [72], in HER2-positive breast cancer.
T-DM1 is an antibody-drug conjugate in which trast-
uzumab is conjugated to a cytotoxic compound, emtansine
(DM1) [73]. T-DM1 combines the mode of action of
trastuzumab with the targeted delivery of a potent cyto-
toxic. Upon binding of the trastuzumab moiety to HER2,
T-DM1 is internalized into the tumor cell, releasing the
DM1 moiety, which inhibits microtubules. A trial is now
underway to examine the efficacy and safety of T-DM1
compared with standard taxane therapy in patients with
HER2-positive gastric cancer [74]. In this study, patients
will be randomized to one of three groups, 3.6 mg/kg
T-DM1 every 3 weeks, 2.4 mg/kg T-DM1 every week, or
standard taxane therapy, for at least four cycles (12 weeks).
Planned endpoints include overall survival, progression-
free survival, duration of response, and time to gastric
cancer symptom progression, as well as safety.
Pertuzumab is a monoclonal antibody that prevents
dimerization of HER2 with other HER receptors [75]. Its
efficacy in combination with trastuzumab in patients with
HER2-positive metastatic breast cancer has been demon-
strated in a phase III clinical trial [72].
The results of these studies are eagerly awaited to
examine the efficacy of this approach in patients with
gastric cancer.
Conclusions
In conclusion, this review has discussed just some of the
abundant data showing the clinical benefits of trastuzumab for
treating HER2-positive breast cancer, including prolonging
overall survival and progression-free survival, and achieving
greater clinical responses. The realization that HER2 is also
overexpressed and/or gene-amplified in other forms of cancer,
notably gastric cancer, has prompted studies in this setting,
and the results accumulated to date indicate that trastuzumab
is effective and tolerable in this setting. Based on the results of
the ToGA trial, an extended indication for trastuzumab in
gastric cancer was approved in Japan in March 2011. The
clinical evidence suggests that trastuzumab monotherapy
could be continued, even in patients who need to discontinue
chemotherapy because of adverse reactions. More data are
still needed, and studies are currently underway to confirm
whether trastuzumab should be continued after disease pro-
gression. The introduction of trastuzumab led to the estab-
lishment of a new disease entity, ‘‘HER2-positive gastric
cancer,’’ similar to HER2-positive breast cancer. It is expected
that more anti-HER2 drugs will be developed and introduced
into clinical practice to treat patients with HER2-positive
cancers, including gastric cancer.
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